Weinhold, N
Heuck, C J
Rosenthal, A
Thanendrarajan, S
Stein, C K
Van Rhee, F
Zangari, M
Hoering, A
Tian, E
Davies, F E
Barlogie, B
Morgan, G J
Article History
Received: 16 June 2015
Revised: 14 October 2015
Accepted: 22 October 2015
First Online: 3 November 2015
Competing interests
: BB and CJH have received research funding from Celgene and Millennium. BB is a consultant to Celgene and Millennium and is a co-inventor on patents and patent applications related to the use of GEP in cancer medicine that have been licensed to Signal Genetics Inc. GJM has participated in advisory boards for, received payment for lectures and development of educational presentations from and has received travel support from Celgene, Novartis, Merck and Johnson & Johnson. FED has participated in advisory boards and spoken at meetings for Celgene, Ortho Biotech and Novartis and has received travel support to attend meetings from Celgene and Ortho Biotech. The remaining authors declare no conflict of interest.